Josie Ursini-Siegel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8732862/publications.pdf

Version: 2024-02-01

25 papers 1,199 citations

16 h-index 24 g-index

25 all docs

25 docs citations

25 times ranked

2690 citing authors

#	Article	IF	CITATIONS
1	POGZ promotes homologyâ€directed DNA repair in an HP1â€dependent manner. EMBO Reports, 2022, 23, e51041.	2.0	9
2	p66ShcA potentiates the cytotoxic response of triple negative breast cancers to PARP inhibitors. JCI Insight, 2021, 6 , $.$	2.3	O
3	Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors. International Journal of Molecular Sciences, 2021, 22, 2608.	1.8	13
4	STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer. Nature Communications, 2021, 12, 3299.	5.8	24
5	CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers. Cancer Research, 2020, 80, 444-457.	0.4	88
6	p66ShcA functions as a contextual promoter of breast cancer metastasis. Breast Cancer Research, 2020, 22, 7.	2.2	10
7	The SHCA adapter protein cooperates with lipoma-preferred partner in the regulation of adhesion dynamics and invadopodia formation. Journal of Biological Chemistry, 2020, 295, 10535-10559.	1.6	10
8	An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy. Nature Communications, 2019, 10, 2139.	5.8	46
9	Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M Gliomas. Cancer Cell, 2019, 35, 782-797.e8.	7.7	143
10	Integration of Distinct ShcA Signaling Complexes Promotes Breast Tumor Growth and Tyrosine Kinase Inhibitor Resistance. Molecular Cancer Research, 2018, 16, 894-908.	1.5	6
11	Translational and HIF-1α-Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides. Cell Metabolism, 2018, 28, 817-832.e8.	7.2	61
12	Interplay between ShcA Signaling and PGC-1α Triggers Targetable Metabolic Vulnerabilities in Breast Cancer. Cancer Research, 2018, 78, 4826-4838.	0.4	10
13	The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression. Nature Communications, 2017, 8, 14638.	5.8	52
14	Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity. Oncotarget, 2017, 8, 57121-57133.	0.8	31
15	The Tyrosine Kinome Dictates Breast Cancer Heterogeneity and Therapeutic Responsiveness. Journal of Cellular Biochemistry, 2016, 117, 1971-1990.	1.2	11
16	The influence of the pre-metastatic niche on breast cancer metastasis. Cancer Letters, 2016, 380, 281-288.	3.2	45
17	STAT3 Establishes an Immunosuppressive Microenvironment during the Early Stages of Breast Carcinogenesis to Promote Tumor Growth and Metastasis. Cancer Research, 2016, 76, 1416-1428.	0.4	87
18	Tungsten Targets the Tumor Microenvironment to Enhance Breast Cancer Metastasis. Toxicological Sciences, 2015, 143, 165-177.	1.4	31

#	Article	IF	CITATIONS
19	The Prognostic Ease and Difficulty of Invasive Breast Carcinoma. Cell Reports, 2014, 9, 129-142.	2.9	64
20	p66ShcA Promotes Breast Cancer Plasticity by Inducing an Epithelial-to-Mesenchymal Transition. Molecular and Cellular Biology, 2014, 34, 3689-3701.	1.1	19
21	Beyond immune surveillance: Stat1 limits tumor growth in a cell-autonomous fashion. Cell Cycle, 2011, 10, 1348-1348.	1.3	3
22	ShcA signalling is essential for tumour progression in mouse models of human breast cancer. EMBO Journal, 2008, 27, 910-920.	3.5	131
23	The ShcA adaptor protein is a critical regulator of breast cancer progression. Cell Cycle, 2008, 7, 1936-1943.	1.3	34
24	Elevated Expression of DecR1 Impairs ErbB2/Neu-Induced Mammary Tumor Development. Molecular and Cellular Biology, 2007, 27, 6361-6371.	1.1	49
25	Insights from transgenic mouse models of ERBB2-induced breast cancer. Nature Reviews Cancer, 2007, 7, 389-397.	12.8	222